ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Submission based on results from pivotal phase III trial showing all primary endpoints met
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Combination shows consistent benefit across prespecified post-progression outcomes
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
Subscribe To Our Newsletter & Stay Updated
